Journal article
Expert Consensus Group report on the use of apomorphine in the treatment of Parkinson's disease - Clinical practice recommendations
C Trenkwalder, KR Chaudhuri, PJ García Ruiz, P LeWitt, R Katzenschlager, F Sixel-Döring, T Henriksen, Á Sesar, W Poewe, M Baker, A Ceballos-Baumann, undefined Deuschl Günther, S Drapier, G Ebersbach, A Evans, H Fernandez, S Isaacson, T van Laar, A Lees, S Lewis Show all
Parkinsonism and Related Disorders | ELSEVIER SCI LTD | Published : 2015
Abstract
Extensive published evidence supports the use of subcutaneously-administered apomorphine as an effective therapy for Parkinson's disease (PD) but to date no consensus recommendations have been available to guide healthcare professionals in the optimal application of apomorphine therapy in clinical practice. This document outlines best-practice recommendations for selecting appropriate candidates for apomorphine intermittent injection (the pen-injection formulation) or apomorphine continuous infusion (the pump formulation), for initiating patients onto therapy and for managing their ongoing treatment.Apomorphine is a suitable therapeutic option for PD patients who experience troublesome 'off'..
View full abstractGrants
Funding Acknowledgements
The Expert Consensus Group was convened and their advisory meetings were supported by Britannia Pharmaceuticals Ltd. Editorial assistance was provided by Dr Karen Wolstencroft, Helen Lawn Associates, supported by Britannia Pharmaceuticals Ltd.